Efficacy and Safety of IVIG-L (Human Normal Immunoglobulin for Intravenous Use)in Idiopathic Thrombocytopenic Purpura (ITP)Patients
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 6
- 主要终点
- The efficacy of IVIG-L
研究概览
简要总结
The efficacy and safety of a liquid intravenous immunoglobulin product, IVIG-L, in patients with ITP will be assessed and compared with data obtained from literature.
详细描述
Sanquin has developed, in cooperation with the Finnish Red Cross Blood Transfusion Service (FRCBTS), a liquid intravenous immunoglobulin product, IVIG-L. The liquid formulation of intravenous immunoglobulin simplifies infusion, eliminates possible mistakes in the reconstitution with water for injection and reduces space requirements in storage.
In addition to donor selection and screening, several procedures have been included in the production process to improve viral safety.
In this clinical trial, the efficacy and safety of IVIG-L in patients with ITP will be assessed and compared with data obtained from literature. IVIG-L will also be studied in patients with hypogammaglobulinemia.The results from both studies will be used for an application for marketing authorisation of IVIG-L in Finland and the Netherlands.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with chronic ITP with a platelet count of about 20x109/L and at high risk of bleeding
- •Patients with chronic ITP with a platelet count of about 20x109/L, who have to undergo surgery
- •A stable clinical situation (no activity of any other disease)
- •Age at least 18 yrs
- •The patient/legally acceptable representative has signed the consent form
排除标准
- •The presence of another autoimmune disease related with thrombocytopenia such as systematic lupus erythematosus (SLE), rheumatoid arthritis (RA) or nephritis
- •Patients with drug-induced thrombocytopenia or immunologic thrombocytopenia of infectious origin (in particular, Hepatitis, Epstein-Barr virus, Toxoplasma, HIV)
- •Massive splenomegaly
- •Treatment with any other investigational drug within 7 days before study entry or previous enrolment in this study
- •Having an ongoing progressive terminal disease, including HIV infection
- •Known with allergic reactions against human plasma, plasma products or intravenous immunoglobulin
- •Presence of conditions predisposing for bleeding: anaemia (hemoglobin < 5.5 mmol/L), renal or urogenital disease, malignant disease (with the exception of basalioma, cervix carcinoma in situ), history of intracranial or aortic aneurysm, stroke, oeso-gastro-intestinal disorders with a bleeding potential, severe hypertension (diastole > 110 mm Hg).
- •Use of corticosteroids for an acute situation within 7 days before study entry. Patients using corticosteroids prophylactically can be included
- •Splenectomy in the previous two weeks
- •Renal insufficiency (plasma creatinine > 115µmol/L)
- •Pregnancy or lactation
- •Known with insufficiency of coronary or cerebral circulation
- •IgA deficiency and anti-IgA antibodies
结局指标
主要结局
The efficacy of IVIG-L
The safety of IVIG-L
次要结局
- To compare data on efficacy and safety of IVIG-L with data obtained from literature